Literature DB >> 15363642

Long-term effect of three different strategies for mass diethylcarbamazine administration in bancroftian filariasis: follow-up at 10 years after treatment.

Dan W Meyrowitsch1, Paul E Simonsen, Stephen M Magesa.   

Abstract

The long-term effect of three different strategies for mass diethylcarbamazine (DEC) administration in bancroftian filariasis was assessed 10 years after start of treatment in three endemic communities in Tanzania. The strategies were the standard 12 day treatment (strategy I); a semi-annual single-dose treatment (strategy II); and a monthly low-dose treatment (strategy III). Treatment was given only during the first year. Following reductions immediately after treatment, overall community microfilaraemia levels were approaching pre-treatment levels in all three communities, 10 years later. In individuals who were microfilaria-positive and treated at baseline, the treatment had a long-term effect on microfilarial intensities, with geometric mean intensities being only 11%, 13% and 2% of pre-treatment levels 10 years later for strategies I, II and III, respectively. This suppressive effect was most pronounced for strategy III, which also cleared microfilaraemia and circulating filarial antigenaemia in a larger proportion of treated individuals than the other strategies. Most of the follow-up individuals who developed microfilaraemia between 2 and 10 years after start of treatment had also been microfilaraemic before treatment, suggesting that reappearance of microfilaraemia may be due to surviving female worms and/or that previously microfilaraemic individuals have a higher chance of reinfection than previously amicrofilaraemic individuals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15363642     DOI: 10.1016/j.trstmh.2004.01.004

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  5 in total

1.  Current evidence on the use of antifilarial agents in the management of bancroftian filariasis.

Authors:  Sumadhya Deepika Fernando; Chaturaka Rodrigo; Senaka Rajapakse
Journal:  J Trop Med       Date:  2010-12-30

2.  Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature.

Authors:  David G Addiss; Molly A Brady
Journal:  Filaria J       Date:  2007-02-15

3.  Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis.

Authors:  Alexander Yaw Debrah; Sabine Mand; Sabine Specht; Yeboah Marfo-Debrekyei; Linda Batsa; Kenneth Pfarr; John Larbi; Bernard Lawson; Mark Taylor; Ohene Adjei; Achim Hoerauf
Journal:  PLoS Pathog       Date:  2006-09       Impact factor: 6.823

4.  Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis.

Authors:  Wilma A Stolk; Quirine A ten Bosch; Sake J de Vlas; Peter U Fischer; Gary J Weil; Ann S Goldman
Journal:  PLoS Negl Trop Dis       Date:  2013-01-03

5.  Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission.

Authors:  Paul E Simonsen; Yahya A Derua; William N Kisinza; Stephen M Magesa; Mwele N Malecela; Erling M Pedersen
Journal:  BMC Infect Dis       Date:  2013-07-21       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.